Published in Cancer Weekly, August 31st, 2004
The study is entitled "PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, has Potent AntiTumor Effects and Augments Antibody-mediated Cytotoxicity via a Novel Immune Mechanism."
The preclinical study showed that talabostat slowed growth or caused regression and rejection of certain experimental tumors in mice in vivo. The authors demonstrated that the antitumor effect of talabostat appears to involve tumor-specific cytotoxic T lymphocytes (CTL) and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.